Specialty Pharmacy

The drug combination demonstrated a 64.5% confirmed objective response rate in individuals with unresectable locally advanced or metastatic urothelial cancer who are ineligible to receive cisplatin-based chemotherapy.

The FDA is evaluating the use of adagrasib (MRTX849) to treat patients with non-small cell lung cancer harboring a KRAS G12C mutation who have previously received at least 1 systemic therapy.

Belimumab (Benlysta) the first FDA-approved therapy for pediatric lupus nephritis.

Pirtobrutinib is under investigation in clinical trials in patients with CLL/small lymphocytic lymphoma, mantle cell lymphoma, and non-Hodgkin lymphoma.

The number of medical visits carried out via telehealth grew from 840,000 in 2019 to 52.7 million in 2020.

FDA accepts supplemental Biologics License Application for Hyrimoz HCF, a biosimilar with the same indications as adalimumab (Humira).

Trastuzumab deruxtecan is an engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

The numbers dropped sharply in March 2020 from before the pandemic among men who have sex with men and individuals who inject drugs.

From a patient perspective, the lack of awareness of biosimilars is the biggest barrier to adoption.

People living with psoriatic arthritis deserve to be informed about ways to approach disease management holistically and with a personalized approach.

Delayed diagnosis in younger individuals and presentation of advanced disease highlights need for awareness.

Progression-free survival was longer with brentuximab vedotin and fewer patients with Hodgkin lymphoma in this group received subsequent therapy.

Tapinarof is a first-in-class topical steroid-free aryl hydrocarbon receptor antagonist intended to mitigate the symptoms of plaque psoriasis.

The evolving landscape of specialty pharmacy growth represents the impact it may have on the operations of the health-system moving forward.

The results showed a 38.1% confirmed objective response rate among HER2-positive patients who received tucatinib in combination with trastuzumab.

Poziotinib is an irreversible pan HER2 inhibitor with activity against mutations of HER1, HER2, and HER4.

Companies that incorporate Diversity, Equity, and Inclusion (DEI) into their everyday operations will be instrumental in shaping a new standard in their workforce and ultimately in society.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

Patients at highest risk of cancer recurrence, including people with lymph node-positive disease, saw the greatest reduction in the risk of recurrence or death with the pertuzumab-based regimen

Organizations such as the Appalachian Community Cancer Alliance are working to leverage technology and improve barriers to care.

Ruxolitinib (Opzelura; Incyte) cream 1.5% is the first and only treatment approved by the FDA for repigmentation in patients with vitiligo.

Tildrakizumab-asmn is a humanized IgG1/k monoclonal anti-IL-23 antibody indicated for the treatment of adults with moderate-to-severe plaque psoriasis.

Health system specialty pharmacies help remove barriers to care, optimize therapy, and improve outcomes.

About one-third of participants in the phase 1b cohort of the KRYSTAL-1 study show an intracranial response, according to Mirati Therapeutics.

The nature of CLL being a long-term, incurable disease makes its treatment a challenge as it is more focused toward improving patient’s quality of life.

With the rapid pace of change in biosimilar payer benefit design, efforts to stay regularly updated on policy changes ahead of time become critical for patient care.

Experts discuss the pros and cons of using oral azacytidine to treat patients with acute myeloid leukemia.

With a lack of head-to-head studies comparing combination regimens in frontline metastatic renal cell carcinoma, deciding on how to choose the right regimen can pose a challenge.

Crizotinib has also been approved to treat non-small cell lung cancer that has spread to other parts of the body and is caused by a defect in either the ALK or ROS1 gene.

Dutch biopharmaceutical company Byondis submitted the BLA for [vic-]trastuzumab duocarmazine (SYD985) in the treatment of patients with HER2-positive metastatic breast cancer with the goal of improving patient outcomes.